Continuous Biofilm Disrupting Materials

连续生物膜破坏材料

• 批准号: 7612392
• 负责人: SHANTHA s SARANGAPANI
• 金额: $ 12.4万
• 依托单位: INNOVATIVE CHEMICAL/ENVIRONMENTAL TECH
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-02-15 至 2010-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7612392
• 关键词: 2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole; Acids; Address; Adherence; Adhesions; Adopted; Adverse reactions; Antibiotics; Area; Binding; Biological; Biological Assay; Blood Vessels; Body Fluids; Butadiene; Calcium; Calcium Binding; Catheters; Chelating Agents; Chlorhexidine; Citrates; Citric Acid; Clinical; Color; Complex; Deposition; Development; Devices; Diffusion; Drug Delivery Systems; Drug Formulations; Drug resistance; Economics; Edetic Acid; Elderly; Environment; Event; Excipients; Filler; Film; Fluorescence Microscopy; Foundations; Funding; Gastrostomy; Goals; Growth; Health Insurance; Health care facility; Hospitals; Hybrids; In Vitro; Industry; Infection; Insurance; Ions; Kinetics; Laboratories; Ligands; Liquid substance; Local Anti-Infective Agents; Magnesium; Marketing; Medical; Medical Device; Methods; Microbial Biofilms; Molds; Morphology; Multi-Drug Resistance; Nature; Nosocomial Infections; Organism; Patients; Permeability; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Plant Resins; Plastics; Play; Polyethylene Glycols; Polymer Chemistry; Polymers; Polysaccharides; Polyurethanes; Population; Powder dose form; Preparation; Process; Property; Proteins; Provider; Publishing; Reporting; Research; Resistance; Role; Sampling; Serum; Silicones; Silver; Solubility; Solutions; Stents; Sulfadiazine; Surface; Synthetic Rubber; System; Technology; Temperature; Therapeutic; Tube; Universities; Washington; Water; Weight; Work; aged; antimicrobial; bacterial resistance; base; conditioning; controlled release; cost; crosslink; experience; hydrophilicity; inhibitor/antagonist; levan; melting; microbial; microbicide; nano; nanosized; novel; pathogen; polycarbonate; pressure; prevent; public health relevance; success; trend

DESCRIPTION (provided by applicant): An increasing pressure to resist the hospital-acquired infection rates by insurance providers is expected to play a crucial role in the growth of the infection resistant treatments and materials according to Frost & Sullivan research. Muti-drug resistant bacterial biofilms pose a constant threat to medical devices and recently the health insurance companies are showing a strong trend of non-coverage of hospital related infection episodes. Technologies such as coating of the catheters or devices with antibiotics or antiseptics like as nano silver, silver sulfadiazine and/or chlorhexidine, antibiotics have been commercialized with limited success due to rapid release rates resulting in depletion of the eluting antimicrobials. Most medical devices such as vascular and other catheters and non-vascular stents are made of thermoplastic medical grade polymers such as polyurethanes. Additives such as colors, inert fillers etc are compounded with a resin under melt conditions, pelletized and then used for extrusion. We propose the idea of incorporating on lab scale, a thermally stable, antimicrobial, biofilm inhibiting formula by compounding it into a medical grade polyurethane followed by extrusion. We will develop compositions with an ability to release active material for up to 30days in sustained manner at effective levels. Such materials could be further optimized to show ultra slow release over several months. (6months is the ultimate target) During the Phase I, for the proof of our concept, we will synthesize and develop formulations that function as antimicrobial inhibitors and form unique silver species that are more soluble and stable in biological media. These will be used as additives at various defined levels into to a medical grade polyurethane matrix using a water insoluble nanosize natural carrier, compounded and processed as flat plastic samples for the Phase I study. We hope to demonstrate a highly controlled long term release from such matrices that provide the surface with biofilm resistance against clinical pathogens in a biological medium with sera. We will create materials with precise concentrations of the active materials and screen them for elution profile, bacterial attachment kinetics and biofilm abrogation. PUBLIC HEALTH RELEVANCE Recent analysis from Frost & Sullivan found that the U.S. antimicrobial treatment markets earned revenues of $175.4M in 2005 with estimates to reach $558.7M by 2012. The market expects to grow with the increasing need to address microbial growth in end-application markets like health care facilities.

描述(由申请人提供)：根据Frost&Sullivan的研究，抵抗保险提供者医院获得的感染率的压力越来越大，预计将在抗感染治疗和材料的增长中发挥关键作用。多重耐药细菌生物被膜对医疗器械构成了持续的威胁，近年来，医保公司出现了医院相关感染事件不覆盖的强烈趋势。诸如在导管或装置上涂上抗生素或纳米银、磺胺嘧啶和/或洗必泰等防腐剂等技术，由于释放速度过快导致洗脱出的抗菌剂耗尽，抗生素的商业化成功有限。大多数医疗设备，如血管和其他导管以及非血管支架，都是由热塑性医用级聚合物如聚氨酯制成的。添加剂，如颜色、惰性填料等，在熔融条件下与树脂复合，造粒，然后用于挤出。我们提出了在实验室规模上加入一种耐热、抗菌、生物被膜抑制配方的想法，将其复合到医用级聚氨酯中，然后挤出。我们将开发能够以有效水平持续释放活性物质长达30天的组合物。这种材料可以进一步优化，在几个月内表现出超缓慢的释放。(6个月是最终目标)在第一阶段，为了证明我们的概念，我们将合成和开发具有抗菌抑制剂功能的配方，并形成在生物介质中更易溶解和稳定的独特银物种。这些材料将作为添加剂在不同定义的水平上加入到医用级聚氨酯基质中，使用不溶于水的纳米级天然载体，作为第一阶段研究的扁平塑料样品进行复合和加工。我们希望展示这种基质的高度受控的长期释放，这种基质在含有血清的生物介质中为表面提供对临床病原体的生物膜抗性。我们将创建具有精确活性物质浓度的材料，并对它们进行洗脱曲线、细菌附着动力学和生物膜去除的筛选。公共卫生相关性Frost&Sullivan最近的分析发现，美国抗菌药物治疗市场在2005年获得了1.754亿美元的收入，预计到2012年将达到5.587亿美元。随着医疗保健设施等终端应用市场解决微生物生长问题的需求日益增加，市场预计将会增长。